Rakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate Update
Rakovina Therapeutics Inc. announced its 2025 financial results and provided a corporate update, highlighting advancements in its AI-powered drug discovery programs and recent leadership appointments. The company is progressing its three primary drug discovery programs toward key milestones, including lead optimization and preclinical testing.
Rakovina Therapeutics Inc., a biopharmaceutical company based in Vancouver, British Columbia, announced its financial results for 2025 and provided a corporate update. The company is advancing its three primary drug discovery programs, kt-5000, kt-3283, and kt-2000, using AI-powered drug discovery. For kt-5000, lead optimization continues with Variational AI, targeting lead candidate selection and IND-enabling studies in the second half of 2026. Rakovina appointed new leadership, including Kim Oishi as CEO and Frank Holler to its Board of Directors. The company closed a non-brokered private placement of convertible debenture units for $1,000,000 and restructured existing debentures, strengthening its balance sheet. Rakovina also expanded its collaboration with Variational AI for continued lead optimization.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.